{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:54:17Z","timestamp":1791561257524,"version":"4.3.4"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Lichenoid amyloidosis (LA), a subtype of primary cutaneous amyloidosis (PCA), is featured by intensely pruritic, hyperkeratotic papules which lacks standardized treatment. Dupilumab, a human monoclonal antibody targeting for interleukin (IL)-4\/13 receptor <jats:italic>\u03b1<\/jats:italic> chain, is widely applied in type 2 inflammation diseases treatment. This article reported two cases of refractory LA successfully treated with dupilumab and reviewed publications reporting dupilumab treatment for PCA.<\/jats:p>","DOI":"10.3389\/fmed.2025.1485079","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T07:35:45Z","timestamp":1738740945000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Dupilumab for treatment of primary cutaneous amyloidosis in adults: two case reports and literature review"],"prefix":"10.3389","volume":"12","author":[{"given":"Feiying","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huajie","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiarong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunli","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s40257-021-00620-9","article-title":"Primary localized cutaneous amyloidosis of keratinocyte origin: an update with emphasis on atypical clinical variants","volume":"22","author":"Hamie","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"323","DOI":"10.4103\/IJPM.IJPM_32_20","article-title":"Primary cutaneous amyloidosis: a clinicopathological, histochemical, and immunohistochemical study","volume":"64","author":"Sinha","year":"2021","journal-title":"Indian J Pathol Microbiol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s40257-017-0278-9","article-title":"Primary localized cutaneous amyloidosis: a systematic treatment review","volume":"18","author":"Weidner","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s40265-017-0768-3","article-title":"Dupilumab: First Global Approval","volume":"77","author":"Shirley","year":"2017","journal-title":"Drugs"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jaad.2020.03.049","article-title":"Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo","volume":"83","author":"Chiricozzi","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1111\/j.1365-2133.2005.06592.x","article-title":"A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis","volume":"152","author":"Reitamo","year":"2005","journal-title":"Br J Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s10103-016-1917-8","article-title":"Treatment of primary cutaneous amyloidosis with laser: a review of the literature","volume":"31","author":"Al Yahya","year":"2016","journal-title":"Lasers Med Sci"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s10103-021-03429-4","article-title":"The therapeutic role of lasers in primary localized cutaneous amyloidosis: a systematic review","volume":"37","author":"Ahramiyanpour","year":"2021","journal-title":"Lasers Med Sci"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1080\/21645515.2019.1582403","article-title":"A review of dupilumab in the treatment of atopic diseases","volume":"15","author":"Thibodeaux","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1007\/s13555-024-01231-y","article-title":"Dupilumab reduces Urticaria activity, itch, and hives in patients with chronic spontaneous Urticaria regardless of baseline serum immunoglobulin E levels","volume":"14","author":"Maurer","year":"2024","journal-title":"Dermatol Ther"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/ced.14059","article-title":"A novel oncostatin M\/interleukin-31 receptor mutation in familial primary localized cutaneous amyloidosis","volume":"45","author":"Adams","year":"2019","journal-title":"Clin Exp Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1111\/bjd.14391","article-title":"Pathophysiology of pruritus in primary localized cutaneous amyloidosis","volume":"174","author":"Tey","year":"2016","journal-title":"Br J Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.5070\/D32612051364","article-title":"Clinical resolution of generalized lichen amyloidosis with dupilumab: a new alternative therapy","volume":"26","author":"Humeda","year":"2020","journal-title":"Dermatol Online J"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e15005","DOI":"10.1111\/dth.15005","article-title":"A case of lichen amyloidosis associated with atopic dermatitis successfully treated with dupilumab: a case report and literature review","volume":"34","author":"Aoki","year":"2021","journal-title":"Dermatol Ther"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e1071","DOI":"10.1111\/jdv.18482","article-title":"Dramatic response to dupilumab in papular amyloidosis","volume":"36","author":"Zahid","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"833","DOI":"10.3390\/life13030833","article-title":"Immunoglobulin G4-related disease-associated dermatitis with pruritus: a positive response to Dupilumab","volume":"13","author":"Beck","year":"2023","journal-title":"Life (Basel)"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.12998\/wjcc.v11.i10.2301","article-title":"Dupilumab for treatment of severe atopic dermatitis accompanied by lichenoid amyloidosis in adults: two case reports","volume":"11","author":"Zhao","year":"2023","journal-title":"World J Clin Cases"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.12998\/wjcc.v11.i11.2549","article-title":"Successful treatment of lichen amyloidosis coexisting with atopic dermatitis by dupilumab: four case reports","volume":"11","author":"Zhu","year":"2023","journal-title":"World J Clin Cases"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3390\/diseases12050094","article-title":"Lichen amyloidosis in an atopic patient treated with Dupilumab: a new therapeutic option","volume":"12","author":"Tirone","year":"2024","journal-title":"Diseases"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1485079\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T07:35:48Z","timestamp":1738740948000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1485079\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,5]]},"references-count":19,"alternative-id":["10.3389\/fmed.2025.1485079"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1485079","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,5]]},"article-number":"1485079"}}